Compare NTB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTB | PHVS |
|---|---|---|
| Founded | 1858 | 2015 |
| Country | Bermuda | Switzerland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2016 | 2020 |
| Metric | NTB | PHVS |
|---|---|---|
| Price | $51.23 | $27.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $53.75 | $39.44 |
| AVG Volume (30 Days) | ★ 138.6K | 94.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.88 | N/A |
| Revenue Next Year | $4.21 | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.86 | $11.51 |
| 52 Week High | $55.84 | $29.80 |
| Indicator | NTB | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 55.50 |
| Support Level | $43.75 | $24.05 |
| Resistance Level | $51.72 | $28.90 |
| Average True Range (ATR) | 1.57 | 1.35 |
| MACD | -0.27 | 0.06 |
| Stochastic Oscillator | 17.71 | 68.86 |
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It offers banking services, comprising retail and corporate banking, and wealth management services, which consist of trust, private banking, and asset management business. The company operates through four reportable segments: Bermuda, Cayman, Channel Islands and the UK, and Other. In its Bermuda and Cayman segments, the company offers retail banking and wealth management services. In the Channel Islands and the UK segment, the company offers retail and corporate banking and wealth management services, and the Other segment includes its operations in the Bahamas, Canada, Mauritius, Singapore, and Switzerland. Maximum revenue for the company is generated from its business in Bermuda.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.